Entrada Therapeutics Inc.

AI Score

XX

Unlock

7.99
-0.81 (-9.20%)
At close: Apr 03, 2025, 3:59 PM
8.02
0.38%
After-hours: Apr 03, 2025, 04:20 PM EDT

Entrada Therapeutics Statistics

Share Statistics

Entrada Therapeutics has 37.59M shares outstanding. The number of shares has increased by 1.26% in one year.

Shares Outstanding 37.59M
Shares Change (YoY) 1.26%
Shares Change (QoQ) 0.47%
Owned by Institutions (%) 75.32%
Shares Floating 21.97M
Failed to Deliver (FTD) Shares 36
FTD / Avg. Volume 0.03%

Short Selling Information

The latest short interest is 1.88M, so 5.02% of the outstanding shares have been sold short.

Short Interest 1.88M
Short % of Shares Out 5.02%
Short % of Float 8.59%
Short Ratio (days to cover) 15.08

Valuation Ratios

The PE ratio is 9.83 and the forward PE ratio is -4.34. Entrada Therapeutics's PEG ratio is -0.01.

PE Ratio 9.83
Forward PE -4.34
PS Ratio 3.06
Forward PS 0.8
PB Ratio 1.5
P/FCF Ratio -14.43
PEG Ratio -0.01
Financial Ratio History

Enterprise Valuation

Entrada Therapeutics has an Enterprise Value (EV) of 603.02M.

EV / Sales 2.86
EV / EBITDA 12.83
EV / EBIT -14.51
EV / FCF -13.49

Financial Position

The company has a current ratio of 11.15, with a Debt / Equity ratio of 0.14.

Current Ratio 11.15
Quick Ratio 11.15
Debt / Equity 0.14
Debt / EBITDA 1.26
Debt / FCF -1.32
Interest Coverage 0

Financial Efficiency

Return on Equity is 15.31% and Return on Invested Capital is 9.39%.

Return on Equity 15.31%
Return on Assets 12.47%
Return on Invested Capital 9.39%
Revenue Per Employee $1.15M
Profits Per Employee $358.61K
Employee Count 183
Asset Turnover 0.4
Inventory Turnover n/a

Taxes

Income Tax 859K
Effective Tax Rate 1.29%

Stock Price Statistics

The stock price has increased by -36.35% in the last 52 weeks. The beta is -0.14, so Entrada Therapeutics's price volatility has been lower than the market average.

Beta -0.14
52-Week Price Change -36.35%
50-Day Moving Average 11.74
200-Day Moving Average 15.4
Relative Strength Index (RSI) 25.55
Average Volume (20 Days) 116.05K

Income Statement

In the last 12 months, Entrada Therapeutics had revenue of 210.78M and earned 65.63M in profits. Earnings per share was 1.76.

Revenue 210.78M
Gross Profit 210.78M
Operating Income 47.01M
Net Income 65.63M
EBITDA 47.01M
EBIT 47.01M
Earnings Per Share (EPS) 1.76
Full Income Statement

Balance Sheet

The company has 101.21M in cash and 59.21M in debt, giving a net cash position of 42M.

Cash & Cash Equivalents 101.21M
Total Debt 59.21M
Net Cash 42M
Retained Earnings -129.34M
Total Assets 526.32M
Working Capital 400.56M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -41.56M and capital expenditures -3.16M, giving a free cash flow of -44.72M.

Operating Cash Flow -41.56M
Capital Expenditures -3.16M
Free Cash Flow -44.72M
FCF Per Share -1.2
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of 22.3% and 31.13%.

Gross Margin 100%
Operating Margin 22.3%
Pretax Margin 31.54%
Profit Margin 31.13%
EBITDA Margin 22.3%
EBIT Margin 22.3%
FCF Margin -21.21%

Dividends & Yields

TRDA does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield 10.17%
FCF Yield -6.93%
Dividend Details

Analyst Forecast

The average price target for TRDA is $28, which is 218.5% higher than the current price. The consensus rating is "Buy".

Price Target $28
Price Target Difference 218.5%
Analyst Consensus Buy
Analyst Count 3
Stock Forecasts

Scores

Altman Z-Score 3.34
Piotroski F-Score 5